Overall, these data support the computational prediction that NOS2 (iNOS) serves as a shared molecular target of both EPO and SPO and demonstrate that both extracts can downregulate iNOS transcription and NO production in inflammatory and tumor cell contexts. This evidence concerns the gene NOS2 and neoplasm.